HIV-1 Drug Resistance Mutation Analyses of Cameroon-Derived Integrase Sequences

被引：0

作者：

Mikasi, Sello Given ^{[1
]}

Isaacs, Darren ^{[2
]}

Ikomey, George Mondinde ^{[3
]}

Shimba, Henerico ^{[1
,4
]}

Cloete, Ruben ^{[3
]}

Jacobs, Graeme Brendon ^{[1
]}

机构：

[1] Stellenbosch Univ, Fac Med & Hlth Sci, Dept Pathol, Div Med Virol, ZA-7505 Cape Town, South Africa

[2] Univ Western Cape, South African Natl Bioinformat Inst, South African Med Res Council, Bioinformat Unit, Cape Town, South Africa

[3] Univ Yaounde I, Fac Med & Biomed Sci, Ctr Study & Control Communicable Dis, Yaounde, Cameroon

[4] Bugando Med Ctr, Mwanza, Tanzania

来源：

AIDS RESEARCH AND HUMAN RETROVIRUSES | 2021年 / 37卷 / 01期

基金：

新加坡国家研究基金会; 英国医学研究理事会;

关键词：

HIV-1; integrase; resistance; Cameroon; diversity; CRF02_AG; DOLUTEGRAVIR; RALTEGRAVIR;

D O I：

10.1089/aid.2020.0022

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

HIV-1 integrase (IN) is a primary target for combination antiretroviral therapy. Only a limited number of studies report on the emergence of resistance-associated mutations (RAMs) in Cameroon. We observed that 1.4% of sequence from treatment-naive patients had IN strand transfer inhibitor (INSTI) RAMs. These mutations confer resistance to raltegravir and elvitegravir. We also observed that 10.1% of the sequences have INSTI accessory RAMs. HIV-1 CRF02_AG was the predominant subtype (44.7%) in this study analyses. The occurrence of INSTI RAMs among the sequences at baseline needs to be monitored carefully.

引用

页码：54 / 56

页数：3

共 50 条

[31] Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase
Mark J. Siedner
Michelle A. Moorhouse
Bryony Simmons
Tulio de Oliveira
Richard Lessells
Jennifer Giandhari
Stephen A. Kemp
Benjamin Chimukangara
Godspower Akpomiemie
Celicia M. Serenata
Willem D. F. Venter
Andrew Hill
Ravindra K. Gupta
Nature Communications, 11
[32] Durable suppression of HIV-1 with resistance mutations to integrase inhibitors by dolutegravir following drug washout
Osman, Nathan
Mesplede, Thibault
Oliveira, Maureen
Hassounah, Said
Wainberg, Mark A.
Brenner, Bluma G.
AIDS, 2018, 32 (13) : 1773 - 1780
[33] Mechanisms of HIV-1 integrase resistance to dolutegravir and potent inhibition of drug-resistant variants
Li, Min
Passos, Dario Oliveira
Shan, Zelin
Smith, Steven J.
Sun, Qinfang
Biswas, Avik
Choudhuri, Indrani
Strutzenberg, Timothy S.
Haldane, Allan
Deng, Nanjie
Li, Zhaoyang
Zhao, Xue Zhi
Briganti, Lorenzo
Kvaratskhelia, Mamuka
Burke Jr, Terrence R. R.
Levy, Ronald M.
Hughes, Stephen H.
Craigie, Robert
Lyumkis, Dmitry
SCIENCE ADVANCES, 2023, 9 (29)
[34] HIV-1 Integrase Inhibitors That Are Active against Drug-Resistant Integrase Mutants
Smith, Steven J.
Zhao, Xue Zhi
Passos, Dario Oliveira
Lyumkis, Dmitry
Burke, Terrence R., Jr.
Hughes, Stephen H.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (09)
[35] Transmission of S230R integrase drug resistance mutation affecting second-generation integrase inhibitors in a French primary HIV-1 infected man
Salmona, Maud
Lascoux-Combe, Caroline
Nere, Marie Laure
Rubenstein, Emma
Molina, Jean Michel
Delaugerre, Constance
Chaix, Marie Laure
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2023, 78 (07) : 1802 - 1803
[36] Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance
Lataillade, M.
Chiarella, J.
Kozal, M. J.
ANTIVIRAL THERAPY, 2006, 11 (05) : S28 - S28
[37] Baseline integrase drug resistance mutations and conserved regions across HIV-1 clades in Cameroon: implications for transition to dolutegravir in resource-limited settings
Semengue, Ezechiel Ngoufack Jagni
Armenia, Daniele
Inzaule, Seth
Santoro, Maria Mercedes
Dambaya, Beatrice
Takou, Desire
Teto, Georges
Nka, Alex Durand
Yagai, Bouba
Fabeni, Lavinia
Chenwi, Collins
Beloumou, Grace Angong
Ndjeyep, Sandrine Claire Djupsa
Colizzi, Vittorio
Perno, Carlo-Federico
Ceccherini-Silberstein, Francesca
Fokam, Joseph
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2021, 76 (05) : 1277 - 1285
[38] Emerging patterns and implications of HIV-1 integrase inhibitor resistance
Geretti, Anna Maria
Armenia, Daniele
Ceccherini-Silberstein, Francesca
CURRENT OPINION IN INFECTIOUS DISEASES, 2012, 25 (06) : 677 - 686
[39] Pathway involving the N155H mutation in HIV-1 integrase leads to dolutegravir resistance
Malet, Isabelle
Ambrosio, Francesca A.
Subra, Frederic
Herrmann, Beatrice
Leh, Herve
Bouger, Marie-Christine
Artese, Anna
Katlama, Christine
Talarico, Carmine
Romeo, Isabella
Alcaro, Stefano
Costa, Giosue
Deprez, Eric
Calvez, Vincent
Marcelin, Anne-Genevieve
Delelis, Olivier
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2018, 73 (05) : 1158 - 1166
[40] Relative fitness of raltegravir resistance mutants in HIV-1 integrase
Hu, Z.
Sun, W.
Yu, T.
Giguel, F.
Kuritzkes, D. R.
ANTIVIRAL THERAPY, 2008, 13 (04) : A84 - A84

← 1 2 3 4 5 →